Latest news for Velo3D (OTC:VLDX) Stock

Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts need, speed their development, and reduce their product costs.

Velo3D Inc

San Francisco-based Distru, a cannabis ERP platform, has closed a successful $6 million Series A funding round. The funding, led and <a href="https://www.prnewswire.com/news-releases/poseidon-portfolio-company-distru-secures-6-million-in-series-a-funding-to-accelerate-growth-and-product-innovation-in-cannabis-erp-302310775.html?tc=eml_cleartime">announced</a> by <a href="https://www.benzinga.com/topic/poseidon-investment-management">Poseidon Investment Managemen</a><a href="https://www.benzinga.com/topic/poseidon-investment-management">t</a>, with additional backing from Global Founders Capital, will accelerate Distru&#8217;s mission to become the go-to platform for cannabis operators across the United States.
<a href="https://www.benzinga.com/markets/cannabis/23/09/34612248/customer-centric-cannabis-platform-new-partnership-drives-sales-efficiency-and-loyalty">Distru</a> has already seen impressive momentum in the cannabis industry, serving operators across 25 states and processing over $2 billion in Gross Merchandise Value (GMV) annually. 
The platform streamlines key business operations such as compliance, inventory management, order workflows, and data-driven decision-making. This has made Distru an essential tool for cannabis businesses seeking to enhance efficiency while staying compliant in a highly regulated market.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/23/09/34612248/customer-centric-cannabis-platform-new-partnership-drives-sales-efficiency-and-loyalty">Customer-Centric Cannabis Platform: New Partnership Drives Sales, Efficiency And Loyalty</a>
Blaine Hatab, co-founder and CEO of Distru, noted &#8220;2024 has been a remarkable year for Distru, marked by efficient growth, achieving strong profitability, and significant product expansion." 
Hatab highlighted recent integrations with major players in the cannabis sector, including Metrc Connect, Dutchie, Treez, Blaze, and Leaflink. The latest funding round, according to Hatab, aims to support further product innovation and expansion, including the integration of new states like New York through Biotrack.
The capital injection is also set to enhance Distru's suite of features, further optimizing compliance, inventory management, and order processing capabilities. 
Poseidon Investment Management's Morgan Paxhia added, "Distru has built the best-in-class Cannabis ERP, and we see that advantage compounding over time." Co-founded by siblings <a href="https://www.benzinga.com/markets/cannabis/22/06/27688513/everything-about-managing-cannabis-investment-founds-meet-emily-paxhia-upcoming-speaker-at-benzi?utm_source=chatgpt.com">Emily</a> and <a href="https://www.benzinga.com/markets/cannabis/24/04/38302710/exclusive-focus-on-selling-numbers-not-dreams-thats-what-makes-cannabis-a-good-investment">Morgan Paxhia</a> in 2013, Poseidon Investment Management is one of the longest-running dedicated cannabis investment funds, known for its diversified strategy across various company stages and industry sub-sectors. 
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">What Is An ERP Platform?</h3>
In case you are not familiar with the term, an ERP (Enterprise Resource Planning) platform is a type of software that helps businesses manage their daily operations. It integrates different functions like accounting, inventory, orders and compliance into one system. This makes it easier for businesses to track and manage everything in one place instead of using multiple separate tools.
In the cannabis industry, an<a href="https://www.benzinga.com/general/24/01/36648157/the-future-of-erp-is-bright-trends-and-predictions-suggest-rapid-business-growth-and-increased-visib"> ERP platform</a> is especially important because the sector is highly <a href="https://www.benzinga.com/topic/cannabis-regulation">regulated</a>. Cannabis businesses must comply with strict laws and regulations, and an ERP system helps them stay on top of compliance requirements. For example, it can track inventory from seed to sale, ensuring that the business follows all legal requirements at each step. 
This is crucial because cannabis businesses need to report data accurately to authorities, like the <a href="https://www.benzinga.com/topic/metrc">Metrc system</a>, which is widely used in the industry.
An ERP platform also streamlines day-to-day operations, helping cannabis companies reduce errors, improve efficiency, and make data-driven decisions. 
With the growing complexity of the <a href="https://www.benzinga.com/cannabis">cannabis industry </a>and its rapid expansion, having an ERP system can help businesses stay organized and compliant while scaling their operations.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/04/38278675/it-all-started-with-cannabis-how-this-innovative-manufacturing-software-firm-is-solving-real-pro">It All Started With Cannabis: How This Innovative Manufacturing Software Firm Is Solving &#8216;Real&#8217; Problem For Its Customers</a></li>
</ul>
Cover: AI-generated image

Cannabis

News

Financing

Markets

This Cannabis Software Co. Secured $6M In A Tight Investment Market, Here's How

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) will release earnings results for its third quarter, after the <a href="https://www.benzinga.com/quote/NVDA/earnings">closing bell on Wednesday, Nov. 20.</a>
Analysts expect the Santa Clara, California-based bank to report quarterly earnings at 75 cents per share, up from 40 cents per share in the year-ago period. Nvidia projects to report revenue of $33.14 billion for the recent quarter, compared to $18.12 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Monday, Nvidia announced it partnered with Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google Quantum AI to accelerate the development of next-generation quantum computing devices.
Nvidia shares gained 3.8% to close at $145.41 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8eb85e9300015f1ae6/william-stein">Truist Securities analyst William Stein</a> maintained a Buy rating and raised the price target from $148 to $167 on Nov. 19. This analyst has an accuracy rate of 87%.</li>
<li>Stifel analyst Ruben Roy maintained a Buy rating and raised the price target from $165 to $180 on Nov. 19. This analyst has an accuracy rate of 86%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5dfcc5e03513fb0001f01095/matt-bryson">Wedbush analyst Matt Bryson</a> maintained an Outperform rating and raised the price target from $138 to $160 on Nov. 14. This analyst has an accuracy rate of 82%.</li>
<li>Raymond James analyst Srini Pajjuri maintained a Strong Buy rating and increased the price target from $140 to $170 on Nov. 14. This analyst has an accuracy rate of 80%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5a12edeeefacff0001e030dc/chris-rolland">Susquehanna analyst Christopher Rolland</a> maintained a Positive rating and boosted the price target from $160 to $180 on Nov. 14. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying NVDA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="556" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20010911/image-199-1024x556.png" alt="" class="wp-image-656305" style="width:683px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20010911/image-199-1024x556.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20010911/image-199-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20010911/image-199-768x417.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/20010911/image-199.png 1212w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>

Earnings

Price Target

Analyst Ratings

Trading Ideas

GOOG

GOOGL

NVDA

Nvidia Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

On Tuesday, Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) highlighted the final results from its VOYAGE Phase&nbsp;2b&nbsp;trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also referred to as metabolic dysfunction-associated steatohepatitis, MASH) at the American Association for the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42074118/viking-therapeutics-presents-results-from-phase-2b-voyage-study-of-vk2809-in-biopsy-confirmed-nash" rel="noreferrer noopener">Study of Liver Disease</a>.
Reduction in Liver Fat Content at 52 Weeks: Patients receiving VK2809 demonstrated statistically significant reductions in liver fat at Week 12, the primary endpoint.
<ul>
<li>Patients receiving VK2809 demonstrated statistically significant reductions in liver fat content at Week 52, with the mean relative change from baseline ranging from 37% to 55%.</li>
<li>The response rate in this study, defined as the proportion of patients experiencing reduction in liver fat ≥30%, ranged from 64% to 88% at Week 52, with all treatment arms demonstrating statistically significant improvement compared to placebo.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" rel="noreferrer noopener">Viking Therapeutics&#8217; Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety</a>
Histologic Results at 52 Weeks
<ul>
<li>On the secondary endpoint of NASH resolution with no worsening of fibrosis, VK2809-treated patients demonstrated NASH resolution ranging from 63% to 75%, compared with 29% for placebo.</li>
<li>Across the combined VK2809 treatment groups, 69% achieved NASH resolution.</li>
<li>On the secondary endpoint evaluating improvement in fibrosis with no worsening of NASH, VK2809-treated patients demonstrated improvement in fibrosis ranging from 44% to 57%, compared with 34% for placebo.</li>
<li>Across the combined VK2809 treatment groups, 51% achieved improvement in fibrosis with no worsening of NASH.</li>
<li>In proportion of patients experiencing both resolution of NASH and improvement in fibrosis, VK2809-treated patients demonstrated improvement ranging from 40% to 50%, compared with 20% for placebo.</li>
<li>Across the combined VK2809 treatment groups, 44% achieved this endpoint.</li>
</ul>
Reduction in Plasma Lipids at Week 52
<ul>
<li>Patients receiving VK2809 demonstrated placebo-adjusted reductions in LDL-C ranging from 20% to 25% and reductions in triglycerides and atherogenic proteins correlated with cardiovascular risk.</li>
</ul>
William Blair notes that VK2735 stands out as a promising candidate for big pharma due to its Phase 3 readiness, the potential for tablet formulation, and Viking&#8217;s amylin program, which is set to begin Phase I trials next year.
While relying on a potential acquisition as an investment strategy is risky, the chances are strong given Viking&#8217;s unique clinical strengths and the significant market potential for chronic metabolic conditions.
The analyst maintains the <a href="https://www.benzinga.com/quote/VKTX/analyst-ratings">Outperform rating on Viking shares.</a>
Price Action: VKTX stock is up 2.48% at $52.79 at last check Wednesday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/11/42089876/nokia-wins-multi-billion-dollar-deal-to-power-airtels-4g-and-5g-expansion-in-india" target="_blank" rel="noreferrer noopener">Nokia Wins Multi-Billion Dollar Deal To Power Airtel&#8217;s 4G And 5G Expansion In India</a></li>
</ul>

Analyst Color

Biotech

Equities

Large Cap

Health Care

Reiteration

General

VKTX

Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs

WIIM

CSGP

CoStar Group shares are trading higher. Needham reiterated a Buy rating on the stock.

Ford shares are trading lower. The company announced 4,000 European job cuts by 2027 and cited weak EV demand, rising competition, and insufficient government support.

Investor sentiment remained subdued on Wednesday as escalating geopolitical tensions weighed on risk assets ahead of the week&#8217;s most anticipated event: Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) third-quarter earnings report, set to be <a href="https://www.benzinga.com/tech/24/11/42093025/will-nvidia-deliver-a-blowout-beat-in-q3-poll-says-maybe-not-but-over-half-see-stock-clearing-150">released after market close.</a>
The market mood deteriorated further after multiple outlets confirmed Ukraine&#8217;s deployment of U.K.-made Storm Shadow missiles into Russian territory, a day after launching U.S.-supplied ATACMS missiles.
The CBOE Volatility Index (VIX), widely regarded as a barometer of market anxiety, spiked over 9%, underscoring rising apprehension among investors. 
Major U.S. indices were in the red, with the tech-heavy Nasdaq 100 leading losses as technology stocks bore the brunt of the sell-off.
The U.S. dollar resumed its upward trajectory, with the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), a proxy for the greenback&#8217;s strength, climbing 0.7%. Safe-haven demand also bolstered gold, which advanced 0.7%, reflecting investors&#8217; flight to safety.
Meanwhile, natural gas emerged as the standout performer among commodities, surging over 6% on the day.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) defied the risk-off sentiment, climbing over 2% to hit a fresh intraday all-time high of $94,989. This propelled its year-to-date gains to an astonishing 123%. 
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,198.51</td>
<td>-0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,886.96</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,311.30</td>
<td>-0.6%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,544.18</td>
<td>-0.7%</td>
</tr>
<tr>
<td>CBOE VIX</td>
<td>17.94</td>
<td>9.7%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.5% to $587.21.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.2% to $432.04.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.6% to $500.28.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.5% to $229.57.</li>
<li>The&nbsp;Health Care Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) outperformed, falling 1%. The&nbsp;Consumer Staples Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 1%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) fell 22% in reaction to a negative earnings report. </li>
<li>Other stocks reacting to earnings included Keysight Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>), up 5.7%; XP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>), down 6%; Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>), up 14%; TJX Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>), down 0.3% and Williams-Sonoma Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>), up 30%.</li>
<li>Apart Nvidia, other large-cap tech companies releasing earnings results after the call are Palo Alto Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) and Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>). </li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/42094649/nvidia-stock-historically-drops-in-december-after-q3-earnings">Nvidia Stock Historically Drops In December After Q3 Earnings</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

Commodities

Politics

Forex

Global

Econ #s

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

KEYS

PANW

SNOW

TSX:XL

PowerShares DB US Dollar Index Bullish Fund

Stocks Fall Ahead Of Nvidia Earnings, Dollar Resumes Gains, Bitcoin Reaches New Record Highs: What's Driving Markets Wednesday?

Amer Sports shares are trading higher after multiple firms maintained Buy ratings on the stock and raised their respective price targets.

Morgan Stanley analyst Tim Hsiao initiated WeRide Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) with an Overweight rating with a <a target="_blank" href="https://www.benzinga.com/quote/WRD/analyst-ratings" rel="noreferrer noopener">price target of $23</a>.
WeRide, a leader in Level 4+ (L4+) autonomous driving technology, is a major player in the global self-driving vehicle sector. The company has achieved significant milestones with its product lineup, including robotaxis, robovans, robobuses, and robosweepers, supported by advanced driver-assistance systems (ADAS).
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42083431/wix-q3-earnings-revenue-hits-4447-million-innovation-fuels-revenue-margin-expansion-and-ai-momentum-fy24-guidance-raised" rel="noreferrer noopener">Wix Q3 Earnings: Revenue Surge, Margin Expansion, AI Momentum, Raised FY24 Guidance &amp; More</a>
Hsiao initiated coverage with an Overweight rating and a price target of $23, underscoring WeRide&#8217;s strong position in the autonomous driving (AD) market and potential for growth.
Founded in 2017, WeRide has established itself as a pioneer in L4+ autonomous driving. It launched China&#8217;s first open-road testing program for L4+ vehicles in 2018 and progressively rolled out its commercial services, starting with robotaxis in 2019, robobuses in 2020, robovans in 2021, and robosweepers in 2022.
The company currently operates in 30 cities across seven countries, including the U.S., China, the UAE, and Singapore, having secured advanced test permits in these regions.
According to CIC forecasts, the global autonomous driving market is expected to grow at an 80% compound annual growth rate (CAGR) from $93 billion in 2025 to $1.745 trillion by 2030.
Within this market, the penetration of L4+ AD technology is projected to exceed 25% by 2035. For China, the AD market is forecasted to expand at an even faster 85% CAGR, reaching $639 billion by 2030.
The analyst writes that WeRide&#8217;s robust product pipeline and partnerships are central to its growth. The company aims to achieve large-scale commercialization of its robotaxi services by 2026, leveraging collaborations such as its partnership with Uber to deploy robotaxis in the UAE.
According to the analyst, the price target of $23 is based on a probability-weighted discounted cash flow (DCF) analysis, assigning weightings of 25% to the bull case, 50% to the base case, and 25% to the bear case.
This valuation reflects WeRide&#8217;s long-term potential while accounting for near-term earnings volatility. The target implies a 30x multiple on 2025 estimated price-to-sales. The company is expected to break even by 2027, the analyst said.
As L4+ autonomous vehicle penetration grows globally, WeRide is well-positioned to capitalize on this trend. With its innovative products, strategic partnerships, and expanding global footprint, WeRide offers a compelling investment opportunity in the autonomous driving sector.
The projected large-scale commercialization of its services by 2026 further cements its long-term growth trajectory.
Hsiao projected fiscal 2024 revenue of 645 million Chinese yuan and EPS loss of (6.19) Chinese yuan. The analyst expects fiscal 2025 revenue of 1.52 billion Chinese yuan and an EPS loss of (4.64) Chinese yuan. He estimates fiscal 2026 revenue of 4.62 billion Chinese yuan and EPS loss of (2.59) Chinese yuan.
Price Action: WRD stock is down 8.14% at $17.72 at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42088437/qualcomm-targets-900-billion-market-by-2030-big-bets-on-iot-and-automotive" target="_blank" rel="noreferrer noopener">Qualcomm Targets $900 Billion Market by 2030: Big Bets on IoT and Automotive</a></li>
</ul>
Image by WeRide

Emerging Markets

Initiation

Movers

WeRide's Robotaxi And Partnerships Are Key Growth Drivers For Global Expansion: Analyst

https://www.cnbc.com/2024/11/20/mcdonalds-preparing-mcvalue-offering-for-2025.html#:~:text=McDonald's%20is%20working%20on%20a,%E2%80%9D%20option%2C%20CNBC%20has%20learned.

JACK

"McDonald's Plans 2025 'McValue' Initiative With $5 Meal Deal And 'Buy One Add One' Option" - CNBC

TECH

Bio-Techne shares are trading higher after the company announced it partnered with Life Sciences to distribute its portfolio across the Arab Gulf states.

Piper Sandler analyst Matt O'Brien maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $235 to $250.

Piper Sandler Maintains Overweight on Penumbra, Raises Price Target to $250

CING

Cingulate shares are trading higher after Maxim Group upgraded the stock from Hold to Buy.

CNBC Halftime Report Final Trades: CNX Resources Corp, EQT Corp, Bitcoin - United States Dollar

Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) stock is moving higher on Wednesday after the company announced its purchase agreements and lease amendments were approved by the <a href="https://www.benzinga.com//node/42087351">Denton City Council on Nov. 19</a>.
The Details: Originally, Core Scientific leased about 31 acres of city-owned land and had access to 297 megawatts (MW) of power. Under the newly approved agreements, Core Scientific has expanded its lease to approximately 78 acres and increased its power access to 394 MW.
&#8220;Denton has been home to one of our most advanced data centers, and now we expect it will host one of the largest GPU supercomputers in North America, powering artificial intelligence,&#8221; said Adam Sullivan, Core Scientific CEO.
 &#8220;We have had a great experience operating in Denton and are grateful for the strong support we&#8217;ve received from the city staff and community members. We look forward to continuing our partnership with the City of Denton as we expand our infrastructure to support high-performance computing.&#8221;
The expansion is expected to result in a $6.1 billion investment in real property.
How To Buy Core Scientific Shares
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Core Scientific's case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
See Also: <a href="https://www.benzinga.com/24/11/42079585/meta-google-and-microsoft-bet-big-on-ai-with-skyrocketing-capex-budgets-but-jensen-huangs-nvidia-poised-to-be-the-biggest-winner-says-analyst-only-game-in-town-with-1-trillion-of-ai-capex">Dan Ives Expects &#8216;Drop The Mic Performance&#8217; Tomorrow From Nvidia: Here&#8217;s Why</a>
CORZ Price Action: At the time of writing, Core Scientific shares are moving 5.34% higher at $17.35, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Shutterstock

Core Scientific, Inc. - Class A Common Stock

CORZ

What's Going On With Core Scientific Shares Wednesday?

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and lowers the price target from $7 to $2.

APTO

HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Lowers Price Target to $2

In the last three months, 6 analysts have published ratings on ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $17.18, a high estimate of $25.00, and a low estimate of $10.50. Experiencing a 1.26% decline, the current average is now lower than the previous average price target of $17.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1732125669_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive ZIM Integrated Shipping is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omar Nokta</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Alexia Dogani</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$13.90</td>
<td>$12.30</td>
</tr>
<tr>
<td>Omar Nokta</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Alexia Dogani</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Underweight</td>
<td>$10.50</td>
<td>-</td>
</tr>
<tr>
<td>Muneeba Kayani</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$13.70</td>
<td>$12.20</td>
</tr>
<tr>
<td>Alexia Dogani</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$15.00</td>
<td>$12.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ZIM Integrated Shipping. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ZIM Integrated Shipping compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for ZIM Integrated Shipping's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ZIM Integrated Shipping's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZIM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ZIM Integrated Shipping analyst ratings.</a>
<h2>Get to Know ZIM Integrated Shipping Better</h2>
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
<h3>Breaking Down ZIM Integrated Shipping's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: ZIM Integrated Shipping's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 47.57%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: ZIM Integrated Shipping's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 19.21%, the company may face hurdles in effective cost management.
Return on Equity (ROE): ZIM Integrated Shipping's ROE stands out, surpassing industry averages. With an impressive ROE of 13.67%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.98%, the company showcases effective utilization of assets.
Debt Management: ZIM Integrated Shipping's debt-to-equity ratio surpasses industry norms, standing at 1.94. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About ZIM Integrated Shipping Stock

Benzinga's options scanner just detected over 8 options trades for HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) summing a total amount of $532,222.
At the same time, our algo caught 6 for a total amount of 637,251.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $315.0 to $335.0 for HCA Healthcare over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for HCA Healthcare's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of HCA Healthcare's whale trades within a strike price range from $315.0 to $335.0 in the last 30 days. 
<h3>HCA Healthcare Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732125645_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.6</td>
<td>$8.4</td>
<td>$8.6</td>
<td>$325.00</td>
<td>$215.7K</td>
<td align="right">86</td>
<td align="right">262</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.6</td>
<td>$9.5</td>
<td>$9.5</td>
<td>$330.00</td>
<td>$139.7K</td>
<td align="right">97</td>
<td align="right">150</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$330.00</td>
<td>$95.9K</td>
<td align="right">97</td>
<td align="right">259</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$18.4</td>
<td>$18.3</td>
<td>$18.4</td>
<td>$335.00</td>
<td>$80.9K</td>
<td align="right">2</td>
<td align="right">36</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.8</td>
<td>$7.2</td>
<td>$7.2</td>
<td>$315.00</td>
<td>$72.7K</td>
<td align="right">410</td>
<td align="right">222</td>
</tr>
</tbody>
</table>

<h3>About HCA Healthcare</h3>
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
Following our analysis of the options activities associated with HCA Healthcare, we pivot to a closer look at the company's own performance.
<h3>Where Is HCA Healthcare Standing Right Now?</h3>
<ul>
<li>With a volume of 505,703, the price of HCA is down -1.79% at $329.1. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 69 days.</li>
</ul>
<h3>What The Experts Say On HCA Healthcare</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $401.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on HCA Healthcare, which currently sits at a price target of $395. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on HCA Healthcare, which currently sits at a price target of $392. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for HCA Healthcare, targeting a price of $420. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on HCA Healthcare, maintaining a target price of $400. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on HCA Healthcare, maintaining a target price of $400. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest HCA Healthcare options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Spotlight on HCA Healthcare: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ULTA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 24 uncommon options trades for Ulta Beauty.
This isn't normal.
The overall sentiment of these big-money traders is split between 29% bullish and 54%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $391,914, and 18 are calls, for a total amount of $1,122,649.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $450.0 for Ulta Beauty over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Ulta Beauty's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Ulta Beauty's substantial trades, within a strike price spectrum from $300.0 to $450.0 over the preceding 30 days.
<h3>Ulta Beauty Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732125640_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ULTA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$21.6</td>
<td>$21.1</td>
<td>$21.6</td>
<td>$310.00</td>
<td>$216.0K</td>
<td>152</td>
<td align="right">100</td>
</tr>
<tr>
<td>ULTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$109.7</td>
<td>$105.6</td>
<td>$107.4</td>
<td>$300.00</td>
<td>$107.4K</td>
<td>1.4K</td>
<td align="right">70</td>
</tr>
<tr>
<td>ULTA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$108.5</td>
<td>$105.2</td>
<td>$107.6</td>
<td>$300.00</td>
<td>$107.1K</td>
<td>1.4K</td>
<td align="right">50</td>
</tr>
<tr>
<td>ULTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$107.6</td>
<td>$105.6</td>
<td>$107.6</td>
<td>$300.00</td>
<td>$86.0K</td>
<td>1.4K</td>
<td align="right">60</td>
</tr>
<tr>
<td>ULTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$110.4</td>
<td>$103.4</td>
<td>$107.6</td>
<td>$300.00</td>
<td>$86.0K</td>
<td>1.4K</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Ulta Beauty</h3>
With 1,385 stores at the end of fiscal 2023 and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the US. The firm offers makeup (41% of 2023 sales), fragrances, skin care (19% of sales), and hair care products (19% of sales), and bath and body items. Ulta offers private-label products and more than 600 individual brands. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Having examined the options trading patterns of Ulta Beauty, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Ulta Beauty</h3>
<ul>
<li>With a trading volume of 392,950, the price of ULTA is up by 0.03%, reaching $342.27.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 15 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Ulta Beauty, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ULTA

A Closer Look at Ulta Beauty's Options Market Dynamics

In the last three months, 11 analysts have published ratings on Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Procter &amp; Gamble, revealing an average target of $171.73, a high estimate of $191.00, and a low estimate of $159.00. Surpassing the previous average price target of $167.25, the current average has increased by 2.68%.
<img src="https://www.benzinga.com/files/images/story/2024/1732125637_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Procter &amp; Gamble. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$191.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Robert Ottenstein</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$164.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$159.00</td>
<td>-</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$174.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$186.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Michael Pohn</td>
<td>DZ Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$190.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Procter &amp; Gamble. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Procter &amp; Gamble compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Procter &amp; Gamble's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Procter &amp; Gamble's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Procter &amp; Gamble analyst ratings.</a>
<h2>About Procter &amp; Gamble</h2>
Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.
<h3>Understanding the Numbers: Procter &amp; Gamble's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Procter &amp; Gamble's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -0.61%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Procter &amp; Gamble's net margin excels beyond industry benchmarks, reaching 17.88%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Procter &amp; Gamble's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 7.73%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Procter &amp; Gamble's ROA excels beyond industry benchmarks, reaching 3.12%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.71, Procter &amp; Gamble adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

11 Analysts Have This To Say About Procter & Gamble

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie.
Looking at options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $1,433,900 and 5, calls, for a total amount of $514,031.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $190.0 for AbbVie over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $150.0 to $190.0 in the last 30 days. 
<h3>AbbVie Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732125634_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.06</td>
<td>$1.31</td>
<td>$1.38</td>
<td>$160.00</td>
<td>$1.2M</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$21.6</td>
<td>$21.55</td>
<td>$21.6</td>
<td>$150.00</td>
<td>$254.8K</td>
<td>14</td>
<td>118</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.4</td>
<td>$1.36</td>
<td>$1.4</td>
<td>$160.00</td>
<td>$145.9K</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.52</td>
<td>$190.00</td>
<td>$130.6K</td>
<td>207</td>
<td>380</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.1</td>
<td>$7.05</td>
<td>$7.05</td>
<td>$165.00</td>
<td>$69.7K</td>
<td>4.1K</td>
<td>116</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>Trading volume stands at 1,463,877, with ABBV's price up by 0.16%, positioned at $166.84.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 72 days.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $215.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $231. 
&#x2A; In a cautious move, an analyst from Wolfe Research downgraded its rating to Outperform, setting a price target of $205. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on AbbVie with a target price of $200. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $215. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $224. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ABBV

Unpacking the Latest Options Trading Trends in AbbVie

Velo3D ( ($VLDX) ) has provided an announcement. Velo3D, Inc., known for its innovative metal 3D printing technology, has transitioned from the New...

Velo3D Shifts to OTCQX Market Post-NYSE Delisting Procedures

Velo3D ( ($VLDX) ) has issued an update. Velo3D, Inc. expanded its Board from nine to ten directors and appointed Darryl C. Porter, an experienced ...

Comments

Velo3D

News

Latest news for Velo3D (OTC:VLDX) Stock

Friday, October 11, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga